Suspected side effects can also be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk
The content reflects publicly available information from Omzo's official website, Terms and Conditions, Shipping Policy, and HIPAA Privacy Policy, supplemented by publicly available regulatory information from FDA.gov and related sources, as of June 2026
Alcohol use A patient with a history of excess alcohol use must be advised to stop consuming alcohol before starting GLP-1 receptor agonist therapy
This product is intended exclusively for in-vitro laboratory and research purposes
That said, do not use this as justification for routinely dosing early
If youve ever found yourself playing detective with your medication dates, youre definitely not alone